Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

Summary: Monoclonal antibodies have potential as rapidly developable agents for treatment and prevention of emerging viruses. The ACTIV-2 trial randomized persons with mild-moderate COVID-19 to the monoclonal antibody combination tixagevimab/cilgavimab via intramuscular injection (600 mg IM) or infu...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Justin Ritz, Michael Gibbs, Hervé Tchouakam Kouekam, Mark T. Esser, Eric S. Daar, Manish Choudhary, Rinki Deo, Courtney V. Fletcher, Jonathan Z. Li, Michael D. Hughes, Davey Smith, David Alain Wohl
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2025-03-01
Serie:	iScience
Soggetti:	Health sciences Medicine Medical specialty Immunology
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2589004225001981
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!